CAMZYOS (mavacamten) should be taken once daily with or without meals at about the same time each day
CAMZYOS (mavacamten) is available in four dose strengths: 2.5 mg, 5 mg, 10 mg, and 15 mg
The capsule should be swallowed whole with water
CAMZYOS (mavacamten) initiation considerations1
Before treatment initiation, patients’ LVEF should be assessed by echocardiography.
If LVEF is <55%, CAMZYOS (mavacamten) should not be initiated
Before initiation of CAMZYOS (mavacamten), women of childbearing potential must be informed of the risk to the foetus, have a negative pregnancy test confirmed, and must use effective contraception during treatment and for 6 months after treatment discontinuation
Patients should be genotyped for CYP2C19 in order to determine appropriate CAMZYOS (mavacamten) dose. Patients with CYP2C19 poor metaboliser phenotype may have increased CAMZYOS (mavacamten) exposures (up to 3 times) that can lead to increased risk of systolic dysfunction compared to normal metabolisers. If treatment initiation occurs prior to determination of CYP2C19 phenotype, patients should follow dosing instructions for poor metabolisers until CYP2C19 phenotype is determined
CAMZYOS (mavacamten) initiation in CYP2C19 intermediate, normal, rapid and ultra-rapid metaboliser phenotypes1
*Interrupt treatment if LVEF is <50% at any clinical visit; restart treatment after 4 weeks if LVEF ≥50%.1
CAMZYOS (mavacamten) initiation in CYP2C19 poor metaboliser phenotype1
*Interrupt treatment if LVEF is <50% at any clinical visit; restart treatment after 4 weeks if LVEF ≥50%.1
Maintenance and Interruption
LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract.
Reference
- CAMZYOS (mavacamten) Summary of Product Characteristics.